Vensica Medical, a pioneering urology therapeutics company, announced the successful closing of an $11 million funding round. The investment will fund the company's upcoming Phase 2 clinical trials across the United States and Europe for its revolutionary treatment of overactive bladder (OAB) using botulinum toxin A (Xeomin) delivered through a proprietary, needle-free device.